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Tuberculosis is still one of the major global public health threats. Countries with low incidence must focus 
on exhausting the reservoir of future cases by preventing reactivation. Therefore, it is important to identify 
and effectively treat those individuals who have latent tuberculosis infection and who may develop active 
disease. The tuberculin skin test has been the standard for detection of immune response against M. 
tuberculosis since the beginning of the 20th century. The new millennium has brought advancement in the 
diagnosis of latent tuberculosis infection. The name of the new blood test is interferon-gamma release 
assay (IGRA). Croatia is a middle-incidence country with a long decreasing trend and developed tuberculosis 
control. To reach low incidence and fi nally eliminate tuberculosis, its tuberculosis programme needs a 
more aggressive approach that would include intensive contact investigation and treatment of persons with 
latent tuberculosis infection. This article discusses the current uses of IGRA and its role in tuberculosis 
control.
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Tuberculosis (TB) control is the most effective if 
TB is detected and treated early. National tuberculosis 
programmes (NTP) in high-incidence countries 
without suffi cient resources are therefore focused on 
early detection and treatment. In turn, tuberculosis 
elimination strategies in low-incidence countries focus 
on exhausting the reservoir of future cases by 
preventing reactivation. They seek to identify and 
effectively treat individuals who have latent 
tuberculosis infection (LTBI) and who may develop 
active disease in their lifetime (1).
Croatia is a middle-incidence country with a long 
decreasing trend and advanced tuberculosis control 
(2). To reach low incidence and fi nally eliminate 
tuberculosis, its NTP needs a more aggressive 
approach that would include intensive contact 
investigation to identify, treat, and follow up 
individuals with LTBI according to the national 
guidelines (3).
There is no possibility to be sure that a person 
thought to have latent tuberculosis infection actually 
carries viable M. tuberculosis (4). What can be 
identified is a cell-mediated memory against 
mycobacterial antigens. For over 100 years this 
immune response against M. tuberculosis has been 
screened for using the tuberculin skin test (TST). It 
involves intradermal injection of purifi ed protein 
derivative (PPD), which is a mixture of more than 200 
50
antigens that lead to a delayed hypersensitivity 
reaction, visible as a local skin induration. The antigen 
spectrum of PPD is shared by the M. tuberculosis 
complex, Bacillus Calmette-Guerin (BCG)-subtype 
of M. bovis, and nontuberculous mycobacteria. As 
BCG vaccination has been a part of the Croatian 
national immunisation programme since 1948, TST 
has shown limited performance in diagnosing LTBI, 
as it gets confounded by prior BCG vaccination. With 
a new test called interferon-gamma release assay 
(IGRA), the new millennium has brought advance in 
identifying immunological response against antigens 
of Mycobacterium tuberculosis to clinical practice and 
tuberculosis control (5). A number of studies, many 
of them referred to in this article, have found IGRA a 
promising assay, but have also raised many questions 
to be answered. This is not surprising, as the nature 
of tuberculosis and immune response are still not fully 
understood.
Tests based on immunological memory, be they 
TST or IGRA, share an important limitation; they do 
not directly detect the presence of M. tuberculosis, but 
identify immune response to recent or remote infection 
with M. tuberculosis (4). However, IGRA overcomes 
the main limitation of TST, which is the lack of species 
specificity. It measures interferon-gamma (IFN-
gamma), a cytokine released by sensitised T-cells in 
response to mycobacterial antigens present in the M. 
tuberculosis complex and absent from the BCG-strain 
and from the most nontuberculous mycobacteria 
except M. kansasii, M. marinum and M. szulgai.
Two types of IGRAs are currently available: the 
ELISpot test (enzyme linked immunospot assay), that 
directly counts the number of IFN-gamma secreting 
T-cells (commercially available as the T-SPOT.TB, 
Oxford Immunotec Ltd, Abingdon, UK) and the 
ELISA test (enzyme linked immunosorbent assay), 
that measures the concentration of secreted IFN-
gamma. Several generations of the ELISA test have 
been developed by Cellestis Ltd, Carnegie, 
Australia.
The fi rst was with PPD as the antigen, which is not 
longer commercially available; the second was 
QuantiFERON®-TB Gold (QFT-G), with early 
secretory antigenic target-6 (ESAT-6) and culture 
f i l t ra te  prote in-10 (CFP-10) ;  and f ina l ly 
QuantiFERON®-TB Gold In-Tube (QFT-G-IT), with 
ESAT-6, CFP-10, and TB7.7.
This latest generation has currently been used in 
Croatia by a limited number of hospitals and public 
health institutes. It is more sensitive than the earlier 
one, probably because of the additional TB7.7 antigen 
(83 % vs. 93 %, p=0.006, respectively) (6).
QFT-G-IT TESTING
The testing procedure is as follows; three millilitres 
of collected blood is distributed in three tubes (1 mL 
each): the nil tube (heparin-only negative control 
tube), the TB antigen tube, and the mitogen tube 
(phytohaemagglutinin positive-control tube). 
Immediately after fi lling, the tubes have to be shaken 
ten (10) times to coat the entire tube wall with blood 
that will solve the antigens on the wall.
Within 16 h of blood collection, the tubes need to 
be incubated for 16 h to 24 h and ELISA test 
performed. The results are software-reported 
automatically as positive if the reaction to TB antigens 
is ≥0.35 IU mL-1 after subtracting the nil control (7). 
This points to a likely M. tuberculosis infection. For 
now, the cut-off of ≥0.35 IU mL-1 IFN-gamma has 
been taken as an optimal combination of sensitivity 
and specifi city. The positive result does not distinguish 
between recent and remote infection or between active 
TB and LTBI. In this respect, it is no better than TST. 
The reason why that QFT-G-IT does not say much 
about the activation of the immune response in 
tuberculosis is that it uses peripheral blood that 
contains much less memory T-cells than the site of 
infection in active disease (8). Therefore, interpretation 
should not rely on the positive result alone, but should 
include risk factors to compensate for suboptimal 
sensitivity and the possibility of cross-reaction with 
three nontuberculous mycobacteria.
A negative result suggests that M. tuberculosis 
infection is not likely. However, if TB is suspected, 
negative result alone can not rule out active disease 
(8). IGRA conversion usually takes four to seven 
weeks following exposure to TB, but conversions can 
also take 14 to 22 weeks (9).
With an indeterminate result, LTBI can neither be 
excluded nor confirmed. If blood cells have not 
responded to a positive control there may have been 
an error in performing the test or the subject’s immune 
system may be suppressed. By including an internal 
positive control (mitogen tube), it is possible to 
distinguish between indeterminate results and those 
that are truly QFT-negative. In contrast, a negative 
TST does not differentiate between immune suppression 
or false test performance and truly negative result (7). 
Indeterminate results are usually associated with 
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young (<5 years) and old (>80 years) age and 
immunosuppression, such as that owed to HIV 
infection or immunosuppressant therapy (10, 11). New 
guidelines recommend to retest the person with 
indeterminate result. If the result remains indeterminate, 
this may point to T-cell anergy (12).
THE MOST IMPORTANT IGRA FEATURES
Many studies have reported on IGRA’s performance. 
They differ in regard to TB incidence, prevalence of 
infection, patient age, status of the immune system, 
prevalence of HIV-coinfection, antigens used (older 
or newer generation), and tuberculin units used during 
TST. This article has focused on newer studies 
published in prestigious scientifi c journals, performed 
in settings similar to ours.
Sensitivity
The sensitivity and specifi city of IGRAs or TST 
for LTBI cannot be reliably estimated because there 
is no gold method for the diagnosis of LTBI. This is 
why two surrogates for infection are used to estimate 
sensitivity. One is active TB. In a recent meta-analysis 
(13), pooled sensitivity of QFT-G-IT, T-SPOT.TB, and 
TST was 80 %, 81 %, and 65 %, respectively. Similar 
meta-analysis are consistent; the sensitivity of both 
IGRAs are usually higher than that of TST (6, 11, 
14-16).
Even though not all individuals exposed to TB will 
become infected, the second approach to estimate 
sensitivity is based on the assumption that some of 
them will, depending on the frequency, length, and 
proximity of contact with infectious TB patient (17). 
Exposure to a TB patient is often used as the infection 
surrogate to estimate test performance in an epidemic 
or contact investigation. Even though more studies 
have estimated T-SPOT.TB sensitivity than that of 
QFT, they all show that both tests better correlate with 
TB exposure than TST and do not depend of BCG 
vaccination (11, 16, 18, 19). To conclude, even though 
either IGRA is more sensitive than TST, their 
sensitivities are suboptimal and we still need to fi nd 
a more sensitive method.
Specifi city
In areas with low TB incidence the prevalence of 
LTBI is expected to be very low among unexposed 
individuals. Therefore, where LTBI has not been 
established, test specifi city is assessed in healthy 
subjects without known exposure. A recent meta-
analysis (20) reported that QFT specifi city ranged 
between 92 % to 100 % and pooled specifi city was 
98 %. Pai et al. (14) reported that pooled specifi city 
of QFT tests was higher among non BCG-vaccinated 
individuals (99 %) than among vaccinated (96 %), 
while pooled specifi city of T-SPOT.TB was 93 %. TST 
specificity was high in populations that had not 
received BCG (97 %), but usually low among BCG-
vaccinated individuals (59 %) (16). Overall, IGRAs 
have a higher specifi city than TST, particularly in 
BCG-vaccinated population.
PREDICTIVE VALUE OF IGRA IN THE 
DEVELOPMENT OF ACTIVE DISEASE
Preventive treatment of IGRA-positive contacts in 
comparison with IGRA-negative contacts will be 
reasonable only if their risk of progression to 
tuberculosis is higher. At the moment, no correlation 
has been established between IFN-gamma responses 
and the stage or degree of infection, the level of 
immune responsiveness, or the probability of 
progression to active disease. However, some fi ndings 
suggest that QFT may be able to predict progression 
to active disease better than TST (21). In recent 
contacts with infectious cases, IGRA-positive tests 
better correlate with M. tuberculosis exposure than 
TST-positive findings. During a follow-up of an 
average of 3.7 years after exposure to TB, 12.9 % of 
QFT-positive contacts who refused chemoprevention 
developed TB in comparison with 3.1 % of TST 
positives (>5 mm of induration) (21). Several studies 
suggest that IGRAs are superior to TST in predicting 
active TB in BCG-vaccinated recent contacts (8, 11). 
However, if active TB is suspected, other diagnostic 
parameters are necessary to confirm TB (eg. 
bacteriological confi rmation).
Higuchi et al. (22) showed that after 3.5 years of 
follow-up, none of BCG-vaccinated contacts who 
were both QFT-negative and TST-positive had 
developed active disease. The negative predictive 
value for M. tuberculosis infection is >95 % for both 
TST and IGRA negative results (23, 24). This suggests 
that LTBI and active TB can be excluded with a high 
degree of certainty in immunocompetent individuals, 
if both tests are performed and both have negative 
results (25). In immunocompromised individuals, 
however, this prediction is very limited (8, 23, 24).
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AGREEMENT BETWEEN IGRA AND TST
Current research has shown that the level of 
agreement between the IGRAs and TST is lower if 
the tested population received BCG. This is not 
surprising because TST is confounded by prior BCG 
vaccination. Agreement between T-SPOT.TB and TST 
is moderate to high, with kappa values ranging from 
0.51 to 0.72, and between QFT test and TST is more 
variable, with kappa values ranging from 0.19 to 0.87 
(11).
However, most studies have focused on the 
agreement in positive vs. negative fi ndings and have 
failed to view results as continuous variables. TST 
induration can be viewed not only as a positive or 
negative outcome, but also as a range of diameters. 
The same goes for INF-gamma results; instead 
dividing them into positive and negative along the 
cut-off value of 0.35 IU mL-1 , they can be compared 
directly. Pai et al. (26) have shown that changes in 
cut-offs of both tests can change the level of their 
agreement.
REPRODUCIBILITY OF IGRA
Reproducibility of IGRAs is particularly interesting 
in terms of within-person variability of T-cell 
responses in serial testings performed in some 
countries (27, 28). IGRAs are highly dynamic tests, 
and T-cell responses, especially weakly positive, tend 
to vary. Conversions, reversions, and non-specifi c 
variations have been reported for both IGRA and TST 
serial testing (18, 29-31). The clinical signifi cance and 
prognosis of IGRA conversion and reversion are not 
clear, and it is diffi cult to determine an optimal cut-off 
to distinguish true infection from biological variability 
(27, 28, 30).
Reproducibility may be evaluated through 
dichotomous (positive vs. negative) results or through 
continuous IFN-gamma values. Reproducibility is 
usually analysed in two ways: a same sample is tested 
by two separate QFT-G-IT assays (so called test-retest 
variability) and the same person is tested repeatedly 
over a short period of time (short-term, within-person 
variability). When QFT-G-IT results are interpreted 
using dichotomous results, then test-retest and within-
person reproducibility are very high, as most of the 
results are well below or well above the cut-off of 0.35 
IU mL-1 IFN-gamma. Discordance is mostly present 
in subjects who had IFN-gamma values around the 
cut-off point (28, 29).
Using continuous IFN-gamma values to interpret 
QFT-G-IT results, reproducibility was moderate to 
high (28) or high (32). A similar study also showed 
that weakly positive IGRA results were subject to 
variation over time more than negative results which 
generally remained negative. Variation in strongly 
positive IFN-gamma values will probably not have 
any clinical signifi cance, but weakly positive IFN-
gamma values may complicate interpretation of 
repeated results (30).
With dichotomous test results, conversion (which 
may lead to LTBI treatment) is simply defi ned as a 
change from negative to positive. Findings from 
reproducibility studies suggest that QFT conversion 
has to meet two conditions: there should be a change 
from a negative to a positive result and the baseline 
IFN-gamma value should increase at least 30 % (28). 
The US Centers for Disease Control and Prevention 
recommend that both the standard qualitative test 
interpretation and the quantitative assay measurement 
should be reported together with the criteria used for 
test interpretation (27).
IGRA IN CHILDREN
In terms of LTBI and active TB, children run a 
high risk of developing active TB after being infected, 
and TB diagnosis is often difficult due to the 
paucibacillary nature of disease. Weak cellular 
immune response is usually the reason why IGRA 
results are more often indeterminate in children than 
in adults (33). Some even prefer TST in diagnosing 
LTBI in smaller children over IGRA (27, 34, 35). This 
preference stems from the fact that TST obtains a 
stronger immunological response, as it stimulates 
central memory cells over a longer incubation time, 
while QFT responses result from effector cells in 
peripheral blood. In addition, the Th1 system, that 
produces interferon-gamma, is immature in children 
while the immune response of the Th2 system 
(interleukin 4, IFN-gamma, tumour necrosis factor 
alpha, interleukin 10, interleukin 12, and granulocyte 
colony-stimulating factor) is active and is more likely 
detected by TST (19, 36). On the other hand, several 
studies suggest that at higher levels of exposure to TB, 
the proportion of children with positive results in both 
IGRAs is higher, independent of the BCG status (11, 
19, 36).
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In a recent meta-analysis (37), pooled sensitivity 
of TST, QFT, and T-SPOT TB in children was 80 %, 
83 %, and 84 %, while pooled specifi city was 85 %, 
91 %, and 94 %, respectively. All tests had lower 
sensitivity in young or HIV-infected children.
An Australian study (19) reported a high level of 
agreement between IGRAs (93 %), but often low 
agreement between IGRAs and TST (75 %). The size 
of TST induration and IFN-gamma levels were 
signifi cantly associated with TB contact history, while 
age infl uenced only the TST results.
One study (38) directly compared T-SPOT.TB, 
Q F T- G - I T,  a n d  T S T  p e r f o r m a n c e  i n 
immunocompromised children in a setting with low 
TB incidence. T-SPOT.TB and QFT-G-IT yielded a 
high percentage of indeterminate fi ndings (13.5 % and 
20 %, respectively) and agreed in 62 % of the cases. 
Excluding the indeterminate results, the IGRAs 
agreement with TST was low and their performance 
was not associated with age, sex, white blood cell 
count, or treatment duration.
Indeterminate results reported for immunocompetent 
children in Italy, tested mostly during contact 
investigation, were more frequent with ELISA-based, 
QFT-G and QFT-G-IT tests than with T-SPOT.TB. 
(12.6 % vs. 2.3 % and 16.4 % vs. 1.5 %, respectively). 
The extent of exposure to M. tuberculosis (household 
vs. casual contacts or recent immigrants) was not 
associated with the rate of indeterminate results for 
any test (33).
In general, studies evaluating IGRA performance 
in children are few, and many questions remain 
unanswered. This is probably the reason why many 
national guidelines recommend caution in the use of 
IGRA in children (UK, Netherlands, Switzerland, 
Canada, France, and Japan) (20).
To conclude, sensitivity may be higher in children 
with a high risk of infection especially in children 
below fi ve years of age and in immunocompromised 
children when IGRA testing is done in addition to the 
TST (4, 39). Whichever test turns positive, it points 
to true infection. Low-risk children may benefi t from 
IGRA as a confi rmation of positive TST in terms of 
increased specificity and reduced risk of a false 
diagnosis of LTBI (4).
IGRA IN IMMUNOCOMPROMISED 
INDIVIDUALS
The risk of progression to active disease is higher 
in infected immunosuppressed patients that in general 
population. Therefore, this is the target group for the 
screening and treatment of LTBI. Different diseases 
and conditions have been found to have impaired 
cell-mediated immunity such as HIV-infection, 
transplantation-related immunosuppressive therapy, 
anti TNF-alpha or corticosteroid treatment, malignancy, 
and chronic renal failure/haemodialysis. Only a 
limited number of studies focused on the accuracy of 
IGRAs in LTBI diagnosis in these groups of 
patients.
HIV-infection is the most important risk factor for 
TB in infected patients. In HIV-positive patients, the 
sensitivity of QFT is generally lower and the 
percentage of indeterminate results higher than in 
HIV-negative individuals. Test sensitivity rises as CD4 
cell count drops. A recent meta-analysis (20) showed 
that IGRA’s pooled sensitivity in HIV-infected TB 
patients was much higher than that of TST (70 % vs. 
45 %, respectively). Another study (40) showed that 
T-SPOT.TB  t e s t  was  pos i t i ve  in  44 .2  % 
immunosuppressed, HIV-negative, non-BCG 
vaccinated persons, who had been nosocomial contacts 
of smear-positive TB patient, while TST was positive 
in 17.4 % (agreement 67.8 %) In addition, T-SPOT.
TB test produced only 4.3 % indeterminate results, 
regardless of the level of immunosuppression.
In a BCG-vaccinated population studied by Kim 
et al. (41), immunosuppression was significantly 
associated with the lower percentage of positive TST 
results (10.3 % in immunocompromised vs. 27.7 in 
immunocompetent patients), but not with positive 
QFT-G-IT results (21.4 % vs. 25.5 %, respectively). 
However, its association was significant with 
indeterminate QFT-G-IT results (21.4 % in 
immunocompromised vs. 9.6 % in immunocompetent 
patients). Indeterminate QFT-G-IT results were 
associated with laboratory fi ndings such as anaemia, 
l ymphocy topen ia ,  hypopro te inemia ,  and 
hypoalbuminemia. The agreement between QFT-G-IT 
and TST was lower in the immunocompromised than 
in the immunocompetent patients.
Generally, only a few studies have addressed the 
performance of IGRAs in these patients. Expert 
opinion is that immunocompromised patients could 
benefi t from the simultaneous use of IGRAs and TST. 
This approach is based on the need to increase test 
sensitivity. Indeterminate fi ndings do not exclude TB 
infection. In fact, an indeterminate result in the 
absence of mitogen response may suggest anergy 
rather than absence of infection (12).
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IGRA RESPONSES DURING THERAPY
In a study by Dyrhol-Riise et al. (42), 85 % of 
patients receiving preventive treatment with isoniazid 
and rifampicin for three months were still positive to 
QFT-G-IT three and 15 months after treatment. 
Moreover, IFN-gamma levels were comparable at 
baseline and the three and 15 months after preventive 
treatment. The authors concluded that the test was not 
useful for monitoring preventive therapy. Similarly, 
Pai et al. (43) showed that 73 % of patients were 
positive to QFT-G-IT at baseline, 81 % after two 
months of treatment, and 79 % at the end of a standard 
six-month treatment.
Changes in IFN-gamma were also inconclusive. 
Both studies suggest that IGRAs are not reliable 
markers to monitor the effect of therapy.
IGRA IN CONTACT INVESTIGATION
The study of QFT-G-IT performance by Dyrhol-
Riise et al. (43) conducted in a low-incidence country 
showed that almost 70 % of the participants with 
positive TST results were QFT-G-IT-negative. The 
highest percentage of QFT-G-IT-positive results was 
found among household contacts (59.5%) and among 
those who had TST induration ≥15 mm (47.5%), 
which is usually taken as a true positive fi nding. 
Positive QFT-G-IT results were associated with 
immigrants born in non-western countries with high 
or intermediate prevalence, then with the time of TB 
exposure, and with previous TB disease.
A large German comparative study (44) of TST, 
QFG-G-IT, and T-SPOT.TB performance in persons 
exposed to pulmonary tuberculosis showed that 
cumulative exposure time, positive smear and/or 
coughing of the source, age, and foreign origin of the 
contact were good predictors of positive QFG-G-IT 
and T-SPOT.TB fi ndings. The two IGRAs agreed in 
93.9 % of cases (κ=0.85). Assuming that positivity to 
both IGRAs was true infection, the sensitivity of TST 
was 72 % and 39.7 % at respective cut-offs of >10 
mm and >15 mm. The authors concluded that either 
QFG-G-IT or T-SPOT.TB would reduce the number 
of LTBI suspects by approximately 70 % in comparison 
with TST. In addition, the authors suggested that 
testing should be limited to contacts of smear-positive 
sources with >8 hours of cumulative exposure and 
contacts of smear-negative sources with >40 hours of 
cumulative exposure. However, the testing should also 
include contacts closely exposed to smear-positive 
sources, regardless of the cumulative time of exposure, 
as this may also lead to LTBI. The authors also pointed 
out that active TB could develop in IGRA-positive 
but TST-negative untreated patients. In other words, 
regardless of the cut-off point, TST may fail to detect 
infected contact. By raising the cut-off from 5 mm to 
10 mm in BCG-vaccinated contacts, 25 % of the tests 
turned false negative and the authors concluded that 
IGRAs were more accurate indicators of LTBI than 
TST. In line with that observation, new German 
guidelines (35) recommend that only IGRA is used to 
test adult contacts who were at least partially BCG-
vaccinated, while TST is preferred for children 
younger than fi ve years.
COST-EFFECTIVENESS ANALYSIS OF 
IGRA IN PRACTICE
A British study (45) compared the cost-effectiveness 
of screening for TB with IGRAs and TST alone and 
in combination. Examining the cost alone, the TST/
IGRA dual strategies cost less than IGRA alone 
strategies (about 160,000 £ vs. 200,000 £ per 1000 
contacts, respectively). However, IGRA alone 
strategies are more specifi c for those who are really 
infected, reduce the number of people who need to be 
treated, and are more effective in preventing post-
exposure TB. When the cost of these strategies is 
compared with effectiveness, the TST/IGRA dual 
strategies are the most cost-effective (approximately 
37,000 £ per one case of prevented TB). TST alone is 
the least cost-effective (approximately 47,500 £ per 
one case of prevented TB). However, dual strategies 
are less effective in preventing active disease than 
screening with IGRA alone (45).
A similar study from Germany (46) also found the 
TST/QFT-G-IT strategy the most cost-effective in 
reducing the disease burden.
IGRA IN NATIONAL TUBERCULOSIS 
PROGRAMMES
Implementation of IGRAs in national tuberculosis 
programmes varies in terms of testing strategies and 
testing inclusion criteria. The US Centers for Disease 
Control and Prevention have suggested replacing TST 
with IGRAs in testing homeless persons, drug users, 
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and persons who have received BCG as a vaccine or 
cancer therapy. Either a TST or an IGRA may be used 
without preference to test contacts of TB patients or 
for periodic screening of persons who might have 
occupational exposure to M. tuberculosis (27). Either 
the TST or an IGRA are recommended in Japan 
(except in children below fi ve years of age), Denmark 
(for child contacts), Australia (for refugees) and 
France. In Switzerland and Denmark IGRA has 
replaced TST in patients receiving anti-TNF-alpha 
therapy. Canada, UK, Italy, Switzerland (for contacts), 
the Netherlands (for contacts and immigrants), Korea, 
Norway (for contacts), and Croatia recommend using 
IGRAs to confi rm positive TST results (3, 34, 47).
BOOSTING EFFECT OF TST ON IGRA
Many studies have pointed out that TST can boost 
IGRA result because both tests contain the same M. 
tuberculosis-specifi c antigens (48-53). This is relevant 
if TST and IGRA are used one after the other, as in 
two-step testings. This boosting effect has been 
observed on day three post TST and later (47, 54), and 
is more pronounced in IGRA-positive individuals. 
However, as many as two to twelve percent of 
otherwise IGRA-negative individuals experience a 
boost to IGRA-positive results after TST, which 
renders interpretation of two-step screening diffi cult 
(47). Current data can not answer when the boosting 
effect of TST on IGRA results stops, but the 
conventional wisdom is that it wanes after three 
months. Van Zyl-Smit et al. (47) conclude that IGRA 
testing performed before or within 72 hours of TST 
will not be subject to the boosting effect. In other 
words, the optimal time to collect blood for IGRA is 
at the time of reading TST.
IGRA IN TESTING HEALTHCARE 
WORKERS
The increased risk of TB in healthcare workers is 
well known (55, 56). In the US, serial screening for 
LTBI is part of the national guidelines and some 
hospital infection control programmes (57). In Croatia, 
healthcare worker screening has been performed only 
as part of contact tracing activities, while regular serial 
screening does not make part of the national 
tuberculosis programme.
Ever since the IGRAs have become part of TB 
screening, there is no general agreement about their 
role for this purpose. Regardless of many advantages 
over TST, the use of IGRAs for serial testing is limited, 
as there are no optimal cut-offs to distinguish new 
infections from nonspecific variations, and it is 
diffi cult to interpret conversion and reversion (29, 
58-62).
Cut-off recommendations range between 
0.2 IU mL-1 and 0.7 IU mL-1 of IFN-gamma, and 
retesting of borderline positive results is recommended 
before LTBI treatment (31, 63). However, many agree 
that repeated results in serial testing should be 
interpreted with caution, especially in countries with 
low TB incidence (31, 62).
CONCLUSIONS AND POLICY 
IMPLICATIONS
Immune-based tests such as TST and IGRAs share 
one important limitation. They do not directly detect 
M. tuberculosis. Instead, they detect remote or recent 
sensitisation to M. tuberculosis. A positive IGRA result 
may not necessarily indicate active tuberculosis, and 
a negative IGRA result does not exclude active 
disease. This also applies to TST. However, the 
negative predictive value of both tests (TST+IGRA 
combined) is high. Their positive predictive value 
depends on the prevalence of M. tuberculosis in a 
given population. Therefore, the gold standard for 
diagnosing active tuberculosis continues to be 
bacteriologically confi rmed M. tuberculosis, but IGRA 
has a great potential in helping to identify LTBI.
The sensitivity of IGRAs may vary, but in general 
it is as high as or higher than TST sensitivity. All 
IGRAs have excellent specifi city, and are certainly 
superior to TST, particularly in BCG-vaccinated 
patients. Furthermore, the agreement between TST 
and IGRAs is the lowest in these patients. Generally, 
the agreement between T-SPOT.TB and TST is higher 
than between QFT and TST, but these fi ndings call for 
further investigation.
Although reproducibility of IGRAs is generally 
high, conversions and reversions may affect 
interpretation and procedures are still unclear in this 
respect.
IGRA sensitivity in children is suboptimal. To 
maximise sensitivity in children with a high risk of 
infection, especially in children below fi ve years of 
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age and in immunocompromised children, IGRA 
testing is recommended in addition to the TST. Low-
risk children may benefi t from IGRAs as a confi rmation 
of the positive TST in terms of increased specifi city 
and reduced risk of a false diagnosis of LTBI. Children 
tend to have more IGRA-indeterminate results, which 
makes interpretation diffi cult.
Expert opinion is that immunocompromised 
patients could benefi t from simultaneous use of IGRAs 
and TST. Indeterminate fi ndings do not exclude TB 
infection. As a compromised immune system is too 
weak to respond to antigen stimulation, indeterminate 
results may actually point to LTBI, although these 
results should not be interpreted as positive.
In contact tracing studies, IGRA showed a good 
correlation with the infectiousness and the intensity 
of exposure to the source. IGRAs should not be used 
in monitoring TB or LTBI therapy or as a test of cure. 
Dual screening strategies (IGRA following positive 
TST) are more cost-effective than TST alone. It is 
generally accepted that TST may boost IGRA results, 
especially if IGRA is performed more than three days 
after TST. Therefore, the optimal time to collect blood 
for IGRA is at the time of TST reading.
IGRAs are an important advancement in the search 
for better diagnostic tests for LTBI. However, their 
performance still leaves much to be desired.
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Sažetak
ULOGA TESTOVA OTPUŠTANJA INTERFERONA GAMA U NADZORU NAD 
TUBERKULOZOM
Tuberkuloza je i danas jedan od vodećih javnozdravstvenih problema. Zemlje s niskom incidencijom 
fokusiraju se na iscrpljivanje rezervoara budućih slučajeva sprječavanjem reaktivacije bolesti. To se odnosi 
na traženje i učinkovito liječenje infi ciranih osoba, primarno onih koje su u riziku od obolijevanja nakon 
infekcije. Tuberkulinski test je od početka 20. stoljeća bio standard u otkrivanju imunosnog odgovora na 
kontakt s Mycobacterium tuberculosis. Novo tisućljeće donijelo je određeni napredak u obliku novih 
testova za dijagnozu latentne tuberkulozne infekcije, krvne testove otpuštanja interferona gama. Hrvatska 
je zemlja srednje incidencije tuberkuloze s dugogodišnjim silaznim trendom i razvijenim protutuberkuloznim 
aktivnostima. U težnji prema niskoj incidenciji i u konačnici eliminaciji tuberkuloze potrebne su opsežnije 
aktivnosti unutar državnog programa nadzora nad tuberkulozom, uključujući intenzivnu obradu kontakata 
i probir na postojanje latentne tuberkulozne infekcije. Ovaj rad razmatra trenutačnu uporabu IGRE (engl. 
interferon - gamma release assay) i njezinu ulogu u nadzoru nad tuberkulozom.
KLJUČNE RIJEČI: Hrvatska, ELISpot, latentna tuberkulozna infekcija, QuantiFERON-TB Gold In-
Tube, tuberkulinski kožni test
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